Zanidatamab
Based on 1 publication(s) in Google Scholar
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.56%
- CAS. Nr.: 2169946-15-8
- Molecular Weight:124.65kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
HER2 |
In Vitro
Zanidatamab (ZW25) has low nM binding affinity (0.9-16 nM) to recombinant HER2 and to cultured cancer cells with a range of HER2 expression[1].
Zanidatamab inhibits the growth of human cancer cell lines with a wide range of HER2 expression (5-54% inhibition depending on the cell line), and inhibits ligand-mediated tumor cell proliferation[1].
Zanidatamab elicits concentration-dependent ADCC at nM potency (0.05-64 nM) with maximal lysis up to 52% on TNBC cell lines expressing HER2 and exhibits synergy and additivity with multiple chemotherapeutic agents including platins, taxanes, microtubule inhibitors, and DNA synthesis inhibitors in various HER2 expressing tumor cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Zanidatamab on AHC2 biosensor, can bind HER2/CD340 Protein, Human (S310Y, HEK293, His, HY-P78680) with an affinity constant of 7.956E-11 M as determined in BLI assay. -
Immobilized Zanidatamab can bind Human Her2/ERBB2 Protein (ECD, His Tag). The EC50 for this effect is 3.09 ng/mL.
Product Details
-
CAS. Nr. 2169946-15-8
-
Accession P04626
-
Synonyms ZW 25; ZW-49 Antibody
-
Molecular Weight 124.65kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
-
Recommend Isotype Controls
-
Format
-
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
98.56%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
MAbs
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo. [Abstract]2024 Jan-Dec;16(1):2412881. PMID: 39381966
Zanidatamab purchased from MedChemExpress. Usage Cited in: MAbs. 2024 Jan-Dec;16(1):2412881. [Abstract]
Head-to-head comparison of KJ015, Zanidatamab (0.01-100 μg/mL, 120 h), and Anbenitamab in MDA-MB-175. All assays were repeated twice.
Zanidatamab purchased from MedChemExpress. Usage Cited in: MAbs. 2024 Jan-Dec;16(1):2412881. [Abstract]
Immunoblots of cell lysates from SK-Br-3 and NCI-N87 cells treated with IgG, Trastuzumab, Pertuzumab, tras+pert, or KJ015 at a final concentration of 50 nM for 24 h. Extra groups of anbenitamab and zanidatamab were added at the same concentration in MDA-MB-175 cells. Actin served as the loading control. T: trastuzumab, P: pertuzumab, T+P: tras+pert, Anbe: anbenitamab, Zani: zanidatamab.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)